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Sputum neutrophilsAbstract Background: Pulmonary ﬁbrosis, the ﬁnal result of a large variety of interstitial lung dis-
eases, is characterized by an aberrant remodeling of extracellular matrix (ECM) with a profound
disturbance of the normal lung architecture. This remodeling includes the exaggerated accumula-
tion of ECM components in the interstitial and alveolar spaces and the disruption of the basement
membranes. It has long been accepted that MMPs play an important role in the pathogenesis of
pulmonary ﬁbrosis, but the exact mechanisms are not well characterized. There are several interre-
lated processes—such as ECM remodeling, basement-membrane disruption, epithelial-cell apopto-
sis, cell migration, and angiogenesis—in which MMPs may play a central role, either by ECM direct
cleavage or by generating bioactive mediators. TIMPs can modulate cellular processes such as cell
growth, apoptosis and migration, and can be both anti- and pro-tumorigenic. This study aimed to
examine the changes in induced sputum as regards MMP-9, TIMP-1 and levels of inﬂammatory
cells in ILD patients compared with sputum of healthy non smokers.
Subjects and methods: Thirty subjects were included in this study and were classiﬁed into the fol-
lowing two groups: Group I included twenty patients diagnosed clinically, radiologically and phys-
iologically as interstitial lung diseases. Group II included ten healthy non smoker subjects. Sputum
induction was done and processed to assess matrix metalloproteinase-9 (MMP-9), tissue inhibitor of
metalloproteinase-1(TIMP-1) and cytological examination with cellular count.
Results: In this study, we have demonstrated that levels of sputum MMP-9 and TIMP-1 were
signiﬁcantly increased in patients with interstitial lung diseases than normal persons with highly
signiﬁcant statistical differences (p= 0.001). MMP-9 was positively correlated with number of
neutrophils in the airway with highly signiﬁcant statistical difference (p= 0.001).
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).rculosis.
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The interstitial lung diseases are a clinically challenging and
diverse group of over 150 disorders characterized by varying
degrees of ﬁbrosis and inﬂammation of the lung parenchyma
or interstitium. The interstitium of the lung spans the region
between alveolar epithelium and pulmonary vascular endothe-
lium. This region includes a variety of cell types (ﬁbroblasts,
myoﬁbroblasts, and macrophages) and matrix components
(collagens, elastin, and proteoglycans) [1]. Pulmonary ﬁbrosis,
the ﬁnal result of a large variety of interstitial lung diseases, is
characterized by an aberrant remodeling of extracellular
matrix (ECM) with a profound disturbance of the normal lung
architecture. This remodeling includes the exaggerated accu-
mulation of ECM components in the interstitial and alveolar
spaces and the disruption of the basement membranes [2].
The pathologic ﬁndings in pulmonary ﬁbrosis (excessive accu-
mulation of ECM and remodeling of the lung architecture) are
a consequence of disturbances in two physiologically balanced
processes: proliferation and apoptosis of ﬁbroblasts and accu-
mulation and breakdown of ECM. When the normal balance
between ECM deposition and turnover is shifted toward depo-
sition or away from breakdown, excessive ECM accumulates
[3]. Several possible origins of ECM producing mesenchymal
cells have been described, and have included accumulation of
resident lung ﬁbroblasts, homing and ﬁbroblastic differentia-
tion of bone marrow- derived cells such as circulating ﬁbro-
cytes or monocytes [4–7], or epithelial-mesenchymal
transition (EMT) [8]. In addition to altered mesenchymal cells,
abnormalities of the alveolar epithelium in patients with pul-
monary ﬁbrosis have been noted from the earliest descriptions
of the disease process [9,10].
Matrix metalloproteinases (MMPs) are a family of zinc
containing endopeptidases, which is a subset of the metzincin
superfamily of metalloproteinases. These regulatory proteases
are the extracellular matrix (ECM) remodelers characterized
by their substrate speciﬁcity to degrade ECM proteins
[11,12]. MMPs can be separated into 6 main classes according
to their substrate speciﬁcity, cellular location and primary
structure: collagenases, gelatinases, stromelysins, matrilysins,
membrane-type MMPs and others [13–15]. Recently, a new
classiﬁcation system has been proposed based on MMP struc-
ture rather than on their substrate speciﬁcity: archetypal
MMPs, matrilysins, gelatinases, and furin activable MMPs
[16,17]. In general, MMPs levels are usually low in normal
adult resting tissues, and with some exceptions, their produc-
tion and activity are maintained at virtually undetectable
levels. By contrast, their expression becomes elevated when
there is a challenge to the system, such as wound healing,
repair or remodeling processes, in diseased tissues and even
in several cell types grown in culture [18].
It has long been accepted that MMPs play an important
role in the pathogenesis of pulmonary ﬁbrosis, but the exact
mechanisms are not well characterized. There are several inter-
related processes—such as ECM remodeling, basement-
membrane disruption, epithelial-cell apoptosis, cell migration,
and angiogenesis—in which MMPs may play a central role,
either by ECM direct cleavage or by generating bioactive
mediators [2]. The participation of MMPs in lung ﬁbrosis
has been analyzed in several interstitial lung diseases in
humans and in experimental models such as those provokedby bleomycin, paraquat plus hyperoxia and silica [19].
MMP-9, also called gelatinase B, contains additionally a type
V collagen like domain that is highly glycosylated, which has
been suggested to have an effect on substrate speciﬁcity [20].
MMP-9 gene expression and protein have also been shown
to be elevated in lungs and BAL ﬂuids from patients with IPF
[21–25]. The majority of MMPs are not expressed in normal
healthy tissues but are expressed in diseased tissues that are
inﬂamed or undergoing repair and remodeling [26,27]. Pul-
monary epithelial cells may also be a signiﬁcant source of
MMPs as they express MMP-1, -2, -7 and -9. Intracellularly,
MMP secretion is primarily regulated by the prostaglandin
(PG) and mitogen activated protein kinase (MAPK) signal
transduction pathways.
Tissue inhibitors of metalloproteinases (TIMP) are a family
of secretory proteins that are able to inhibit matrix metallo-
proteinase activities through non-covalent binding of pre- or
active forms of MMPs at molar equivalence. By inhibiting
MMPs, TIMPs may also inﬂuence MMP-mediated processes
such as processing of cytokines, degradation of growth factor
binding proteins, and the release of ECM-bound growth fac-
tors [11,28–31]. TIMPs can modulate cellular processes such
as cell growth, apoptosis and migration, and can be both
anti- and pro-tumorigenic [11,13,32,33]. TIMP-1 works as a
natural inhibitor of MMP-9 and is found in most tissues and
body ﬂuids. By inhibiting MMPs activities, TIMPs are
involved in tissue remodeling and regulation of ECM metabo-
lism. The TIMP family consists of four members sharing
important structural features as well as the ability of MMP
inhibition [11,13].
Induced sputum (IS) collection is a non-invasive method
for assessment of airway inﬂammation in the airways [34,35].
This study aimed to examine the changes in induced sputum
as regards MMP-9, TIMP-1 and levels of inﬂammatory cells
in ILD patients compared with sputum of healthy non
smokers.
Subjects and methods
Subjects
Thirty subjects were included in this study and were classiﬁed
into the following two groups: Group I included twenty
patients diagnosed clinically, radiologically and physiologi-
cally as interstitial lung diseases. Group II included ten healthy
subjects. Patients with history of COPD, bronchial asthma or
recent respiratory tract infection were excluded from this
study.
Methods
A written informed consent was obtained from all subjects.
The two groups underwent full history taking including history
of smoking (current, ex, and non smoking), history of chest
symptoms (cough, expectoration, wheezes and dyspnea) and
history of any other co morbidities. Also full clinical examina-
tion (general, full local respiratory system examination includ-
ing inspection, palpation, percussion and auscultation, with
special regards to manifestations of right sided heart failure
as lower limbs edema, congested neck veins, tenderness over
right hypochondrium, and dullness on right parasternal area)
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spirometry. Flow/volume loop was performed in all cases.
Computerized tomography CT was done to group one to con-
ﬁrm diagnosis of interstitial pulmonary diseases. Sputum
induction was done and was processed to assess matrix
metalloproteinase-9 (MMP-9) by ELISA (MMP-9 BIOTRAK
ELISA), tissue inhibitor of metalloproteinase-1(TIMP-1) by
ELISA (TIMP-1 BIOTRAK ELISA), cytological examination
and cellular count. The total and the differential cell counts
were expressed as corrected percentage. Routine laboratory
investigations (CBC, Liver enzymes and serum creatinine)
were also done. Sputum Induction and Processing were done
according to Esa et al. [11].
The assay of matrix metalloproteinases-9 in sputum is done
by ELISA
Principles of assay
The RayBio human MMP-9 ELISA (enzyme-linked
immunosorbent assay) kit is an in vitro enzyme-linked
immunosorbent assay for the quantitative measurement of
human MMP-9. This assay employs an antibody speciﬁc for
human MMP-9 coated on a 96-well plate. Standards and sam-
ples are pipetted into the wells and MMP-9 present in the sam-
ple is bound to the wells by the immobilized antibody. The
wells are washed and biotinylated anti-human MMP-9 anti-
body is added. After washing away unbound biotinylated anti-
body, HRP-conjugated streptavidin is pipetted into the wells.
The wells are again washed, a TMB substrate solution is added
to the wells and color develops in proportion to the amount
of MMP-9 bound. The stop solution changes the color from
blue to yellow, and the intensity of the color is measured at
450 nm [36].
Assay procedure
All reagents and samples were brought to room temperature
(18–25 C) before use. 100 ll of each standard (see Reagent
Preparation step 2) and sample was added into appropriate
wells, covered well and incubated for 2.5 h at room tempera-
ture. The wells were washed 4 times with 1x wash solution
(200 ll each).100 ll of 1 prepared biotinylated antibody
was added to each well and incubated for 1 h at room temper-
ature. The solution was discarded and washed 4 times with 1
wash solution (200 ll each). 100 ll of prepared Streptavidin
solution was added to each well and incubated for 45 min at
room temperature. The solution was discarded and washed 5
times with 1 wash solution (200 ll each). 100 ll of TMB
One-Step Substrate Reagent was added to each well and incu-
bated for 30 min at room temperature in the dark. 50 ll of
Stop Solution was added to each well then the absorbance
was read at 450 nm immediately. The concentration of
MMP-9 was calculated from the standard curve.
The assay of tissue inhibitor metalloproteinases-1in sputum
is done by ELISA
Principles of assay
The RayBio human TIMP-1 ELISA (enzyme-linked
immunosorbent assay) kit is an in vitro enzyme-linked
immunosorbent assay for the quantitative measurement of
human TIMP-1. This assay employs an antibody speciﬁc forhuman TIMP-1 coated on a 96-well plate. Standards and sam-
ples are pipetted into the wells and TIMP-1 present in the sam-
ple is bound to the wells by the immobilized antibody. The
wells are washed and biotinylated anti-human TIMP-1 anti-
body is added. After washing away unbound biotinylated anti-
body, HRP-conjugated Streptavidin is pipetted into the wells.
The wells are again washed, a TMB substrate solution is added
to the wells and color develops in proportion to the amount of
TIMP-1 bound. The stop solution changes the color from blue
to yellow, and the intensity of the color is measured at 450 nm
[37].
Assay procedure
All reagents and samples were brought to room temperature
(18–25 C) before use. 100 ll of each standard (see Reagent
Preparation step 2) and sample was added into appropriate
wells, covered and incubated for 2.5 h at room temperature.
The solution was discarded and washed 4 times with 1x wash
solution (200 ll each). 100 ll of 1 prepared biotinylated anti-
body was added to each well and incubated for 1 h at room
temperature. The solution was discarded and washed 4 times
with 1 wash solution (200 ll each). 100 ll of prepared Strep-
tavidin solution was added to each well and incubated for
45 min at room temperature. The solution was discarded and
washed 5 times with 1x wash solution (200 ll each). 100 ll of
TMB One-Step Substrate Reagent was added to each well
and incubated for 30 min at room temperature in the dark.
50 ll of Stop Solution was added to each well then the absor-
bance was read at 450 nm immediately. The concentration of
TIMP-1 was calculated from the standard curve.
Statistical analysis
Quantitative data were presented as mean and standard devi-
ation (SD) values. Student’s t-test used for comparisons
between mean of two groups. Inter-group comparison of cate-
gorical data was performed by using ﬁsher exact test (FET).
Qualitative data were presented as frequencies and percent-
ages. Pearson’s correlation coefficient was used to determine
signiﬁcant correlations between the different variables. The
signiﬁcance level was set at p 6 0.05. Statistical analysis was
performed with SPSS version 19.0 (statistical package for
scientiﬁc studies) for windows.
Results
This study was done in the chest department of university hos-
pital in the period between August 2011 and August 2014.
Thirty subjects were included in this study and were classiﬁed
into the following two groups: Group I included twenty
patients diagnosed clinically, radiologically and physiologi-
cally as interstitial lung diseases. Group II included ten healthy
non smoker subjects. Patients’ demographic data are shown in
Table 1. Group I included 14 (70%) male patients and 6 (30%)
female patients with a mean age of 49.15 ± 3.12. The control
included 10 (100%) male patients with a mean age of 48.3
± 3.4. There was no signiﬁcant statistical difference of mean
ages between both groups. Patients’ laboratory data are shown
in Table 1. Total leukocytic count in sputum was signiﬁcantly
higher in group I (23.36 ± 4.53) than in the control group
(17.38 ± 1.95). Neutrophils, eosinophils and lymphocytes
Table 1 Patients’ demographic data, laboratory results and PFT of both groups.
Variable Group (I) ILD (20 cases)
Mean ± SD
Group (II) control group
Mean ± SD
p-Value
Age 49.15 ± 3.12 48.3 ± 3.4 0.5
Sex, n (%)
Male 14 (70.0) 10 (100) 0.146
Female 6 (30.0) 0 (0.0)
MMP9 242.05 ± 16.7 29.5 ± 10.05 0.001**
TIMP1 1493.0 ± 135.4 91.2 ± 36.36 0.001**
MMP9/TIMP1 0.163 ± 0.015 0.315 ± 0.036 0.001**
TLC 23.36 ± 4.53 17.38 ± 1.95 0.001**
Neutrophiles 61.44 ± 2.98 21.93 ± 3.74 0.001**
Eosinophiles 1.12 ± 0.41 0.50 ± 0.29 0.001**
Macrocytes 34.6 ± 2.91 75.53 ± 4.18 0.001**
Lymphocytes 2.77 ± 0.96 1.97 ± 0.92 0.001**
FEV1 1.2 ± 0.58 3.15 ± 0.32 0.037*
FEV1% 34.05 ± 16.93 89.8 ± 4.61 0.001**
FVC 1.34 ± 0.59 4.06 ± 0.51 0.001**
FVC% 31.25 ± 15.62 87.5 ± 5.13 0.001**
FEV1/FVC 85.7 ± 11.22 75.4 ± 2.12 0.008**
* Signiﬁcant.
** Highly signiﬁcant.
Table 2 Correlation between sputum MMP-9, TIMP-1 and ratio of MMP-9/TIMP1 with different variables in group (I).
Variables MMP-9 (ng/ml) TIMP-1 (ng/ml) MMP-9/TIMP-1
(r) p (r) p (r) p
FVC% 0.405 0.077 0.194 0.413 0.486 0.03*
FEV1/FVC% 0.034 0.885 0.244 0.30 0.230 0.33
Neutrophiles 0.993 0.001** 0.324 0.163 0.417 0.067
Eosinophiles 0.121 0.61 0.359 0.120 0.267 0.254
Macrocytes 0.959 0.001** 0.303 0.195 0.413 0.071
Lymphocytes 0.242 0.303 0.069 0.774 0.118 0.621
* Signiﬁcant = less than 0.05.
** Highly signiﬁcant = less than 0.01.
306 S.A. Esa et al.were statistically highly signiﬁcant more in group 1 than in the
control group, while alveolar macrophages were statistically
highly signiﬁcant lower in group I than that in the control
group. Sputum MMP-9 was statistically highly signiﬁcant
higher in group 1 with a mean value of 242.05 ± 16.7 than
in the control group with a mean value of 29.5 ± 10.05. Also
sputum TIMP-1 was statistically highly signiﬁcant higher in
group I with a mean value of 1493.0 ± 135.4 than in the con-
trol group with a mean value of 91.2 ± 36.36. Pulmonary
function tests are shown in Table 1. Forced vital capacity
(FVC) and forced expiratory volume in ﬁrst seconds (FEV1)
were signiﬁcantly lower than that in the control group while
the ratio of FEV1/FVC was signiﬁcantly higher in group 1
than in the control group.
The correlation between inﬂammatory markers and differ-
ent variables in group 1 is shown in Table 2 and Fig. 1. There
was a positive correlation with highly signiﬁcant statistical dif-
ference between neutrophils and MMP-9. Alveolar macro-
phages showed negative correlation with highly signiﬁcant
difference with MMP-9. As regards TIMP-1 and ratio of
MMP-9/TIMP-1, neutrophils showed positive correlation with
no signiﬁcant difference while alveolar macrophages showed
negative correlation with no signiﬁcant difference. FVC%
showed positive correlation with MMP-9 and MMP9-9/TIMP-1 ratio with highly signiﬁcant statistical difference with
MMP-9/TIMP-1. The CT ﬁndings and ﬁnal diagnosis of group
(I) are shown in Table 3. Fifteen cases were diagnosed with
IPF, three cases NSIP (nonspeciﬁc interstitial pneumonia),
one case sarcoidosis and one case rheumatoid arthritis. The
diagnosis was conﬁrmed in some cases by biopsy but in other
cases by associated laboratory and radiological ﬁndings.Discussion
Pulmonary ﬁbrosis is a chronic lung disease characterized
pathologically by excessive accumulation of extracellular
matrix (ECM) and remodeling of the lung architecture, and
additionally characterized by recognizable clinical, physio-
logic, and radiographic ﬁndings [3]. Dysregulated pulmonary
matrix remodeling resulting from failure to adequately repair
damage caused by chronic inﬂammation is felt to underlie
the development of pulmonary ﬁbrosis. Excessive degradation
can trigger the unregulated production of the matrix compo-
nent that characterizes ﬁbrosis [38].
MMPs are capable of degrading various components of the
connective tissue matrix, and TIMPs are believed to play a sig-
niﬁcant role in remodeling after parenchymal damage, which
Figure 1 Correlation between sputum inﬂammatory markers (MMP-9, TIMP-1, MMP-/TIMP1) with FVC% and neutrophils in
group (I).
Study of metalloproteinase-9 and metaloprotienase-1 in patients with lung diseases 307results in tissue destruction or in the induction of repair pro-
cesses in pulmonary disease [22,39,40]. Among the MMPs,
MMP-9 possesses the capacity to preferentially degrade colla-
gen type IV, entactin, collagen type VII, as well as collagen
type V in the interaction with interstitial ﬁbrillar collagens
[41,42]. The level of MMP-9 in the air spaces may relate to
the degree of severity of inﬂammation of lung disease [43,44].
In this study, we have demonstrated that levels of sputum
MMP-9 and TIMP-1 were signiﬁcantly increased in patients
with interstitial lung diseases than normal persons with highly
signiﬁcant statistical differences. These results were in agree-
ment with the results obtained from previous studies [38,45].
In this study MMP-9 levels were positively correlated with spu-
tum neutrophils. It is tempting to speculate that neutrophils
are the major source of MMP- 9 in the airways of those
patients. This result was matched with another study that
investigated MMP-9 in COPD and IPF [46]. MMP-9 may pro-
voke the disruption of basement membranes, which seems tobe an important event in IPF pathogenesis that enhances the
ﬁbroblast invasion into the alveolar spaces. In addition, the
disruption of the basement membrane may also contribute to
the failure of an orderly repair of the damaged alveolar type
I epithelial cells, affecting normal reepithelialization and,
moreover, it may have an additional deleterious role by induc-
ing epithelial apoptosis [2]. In fact, the integrity of the base-
ment membrane is required to suppress programed cell death
as has been demonstrated in mammary epithelium and other
tissues [2]. MMP-9 gene expression and protein have also been
shown to be elevated in lungs and BAL ﬂuids from patients
with IPF [21,23]. The enzyme has been localized in epithelial
cells, neutrophils, and macrophages with some staining in
subepithelial ﬁbroblasts.
The source of airway TIMP-1 in our patients remains
unclear, since there was positive correlation between TIMP-1
and neutrophils but with no signiﬁcant statistical difference.
Possible sources of TIMP-1 could be cellular components of
Table 3 CT ﬁndings and ﬁnal diagnosis of group (I) ILD.
Number
of cases
CT ﬁnding Final diagnosis
15 cases Peripheral, subpleural and, Basal
distribution of:
Reticular opacities (ﬁbrosis),
Honeycombing, Traction
bronchiectasis, Architectural
distortion, Minimal focal ground
glass appearance
Idiopathic
pulmonary ﬁbrosis
(IPF)
3 cases Peripheral, subpleural, basal,
symmetric diﬀuse ground glass
opacities, ﬁne reticulations and
minimal honeycombing
NSIP (nonspeciﬁc
interstitial
pneumonia)
1 case Upper and mid lung distribution
of:
Micronodular opacities along
septae, peribronchovascular
bundles and pleura Irregular
linear opacities, Ground-glass
opacities, Honeycombing, Hilar
and mediastinal, adenopathy
Sarcoidosis
1 case Subpleural basal reticular pattern
Pleural thickening, Ground-glass
opacities, Honeycombing
Rheumatoid
arthritis
308 S.A. Esa et al.the extracellular matrix, like ﬁbroblasts or myoﬁbroblasts [47],
or epithelial cells. Sputum alveolar macrophages were nega-
tively correlated with all markers (MMP-9, TIMP-1 and molar
their ratio). These ﬁndings explore that alveolar macrophages
were decreased in all cases of pulmonary ﬁbrosis. These ﬁnd-
ings matched with previous studies [38,46]. The molar ratio
of MMP-9/TIMP-1 was signiﬁcantly lower in ILD group than
in the control group. It means that the imbalance between
MMP-9 and its inhibitor TIMP-1 may play a role in tissue
remodeling and lung ﬁbrosis.
The molar ratio of MMP-9/TIMP-1 correlated with the
number of neutrophils (r= 0.417 and p= 0.067). This is a
marginally acceptable correlation, most likely due to the small
sample size. These data suggest that the number of neutrophils
may be more closely related to levels of MMP-9 than to levels
of TIMP-1.
Conclusion
MMP-9 and TIMP-1 were signiﬁcantly increased in pul-
monary ﬁbrosis. MMP-9 was positively correlated with the
number of neutrophils in the airway and is responsible for pul-
monary injury while TIMP-1 is responsible for airway remod-
eling and failure to repair. MMP-9 and its cognitive inhibitor
TIMP-1 may play a signiﬁcant role in the process of lung ﬁbro-
sis resulting from different etiologies.
Limitations
Small sample size and variable causes of pulmonary ﬁbrosis.
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